Cargando…
ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome
Mucopolysaccharidosis type I (MPS I) is a severe disease due to deficiency of the lysosomal hydrolase α-L-iduronidase (IDUA) and the subsequent accumulation of the glycosaminoglycans (GAG), leading to progressive, systemic disease and a shortened lifespan. Current treatment options consist of hemato...
Autores principales: | Ou, Li, DeKelver, Russell C., Rohde, Michelle, Tom, Susan, Radeke, Robert, St. Martin, Susan J., Santiago, Yolanda, Sproul, Scott, Przybilla, Michael J., Koniar, Brenda L., Podetz-Pedersen, Kelly M., Laoharawee, Kanut, Cooksley, Renee D., Meyer, Kathleen E., Holmes, Michael C., McIvor, R. Scott, Wechsler, Thomas, Whitley, Chester B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319315/ https://www.ncbi.nlm.nih.gov/pubmed/30528089 http://dx.doi.org/10.1016/j.ymthe.2018.10.018 |
Ejemplares similares
-
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing
por: Laoharawee, Kanut, et al.
Publicado: (2018) -
Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome
por: Laoharawee, Kanut, et al.
Publicado: (2023) -
Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I
por: Ou, Li, et al.
Publicado: (2016) -
ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice
por: Pagant, Silvere, et al.
Publicado: (2021) -
Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome
por: Shapiro, Elsa G., et al.
Publicado: (2018)